Zydus Wellness
- Market Cap
- ₹14,255 Cr
- P/E
- 57.89
Key Fundamentals
SmallcapFood ProductsFMCGPrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 4.91%
- Debt to Equity
- 0.54
- EPS (TTM)
- ₹7.74
- Book Value
- ₹185.69
- Market Cap
- ₹14,255 Cr
- P/E (TTM)
- 57.89
- P/B
- 2.41
- ROE
- 3.98%
- Dividend Yield
- 0.26%
- EBITDA
- ₹516 Cr
- 52W High
- ₹611.85
- 52W Low
- ₹367.55
- Day Range
- ₹443.65 – ₹459.55
- Volume
- 1,40,918
Peer Comparison
Fast Moving Consumer Goods › Food Products › Packaged Foods
| 1,325.00 | 61.80 | 2,55,502 | 42.85 | 1.09% | 73.20% | 84.10% | 25,581 | 4,134 | |
| 4,900.00 | 44.20 | 1,18,025 | 27.78 | 1.94% | 53.50% | 56.00% | 20,286 | 2,681 | |
| 448.05 | 57.89 | 14,255 | 2.41 | 0.26% | 3.98% | 4.91% | 5,013 | 246 | |
| 508.95 | 48.43 | 12,761 | 7.18 | 0.26% | 17.80% | 22.00% | 2,949 | 264 | |
| 1,310.20 | 7.05 | 9,142 | 1.19 | 1.29% | 19.00% | 33.00% | 20,671 | 2,629 | |
| 221.50 | 43.09 | 6,800 | 5.10 | 0.60% | 11.50% | 14.10% | 2,198 | 158 | |
| 265.83 | 31.84 | 3,314 | 6.17 | 0.19% | 9.64% | 11.70% | 1,694 | 104 | |
| Median 7 companies | 508.95 | 44.20 | 12,761 | 6.17 | 0.60% | 17.80% | 22.00% | 5,013 | 264 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 51
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 31
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 38
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 44
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 56
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company is expected to give good quarter
Weaknesses
2- Company has a low return on equity of 5.09% over last 3 years.
- Dividend payout has been low at 14.1% of profits over last 3 years
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 4 | 3 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 35.36
- Neutral
- MACD (12,26,9)
- −11.17
- Bearish
- SMA (50)
- 497.22
- Bearish
- SMA (200)
- 493.94
- Bearish
As of
Analyst Rating
6 of 7 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +25.86% |
|---|---|
| 5Y | +16.23% |
| 3Y | +20.66% |
| 1Y | +46.22% |
| TTM | +73.68% |
Net profit
| 10Y | +6.49% |
|---|---|
| 5Y | +10.61% |
| 3Y | −14.03% |
| 1Y | −43.23% |
| TTM | −2.88% |
Operating cash flow
| 10Y | +9.64% |
|---|---|
| 5Y | −4.67% |
| 3Y | +34.93% |
| 1Y | −40.53% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −10.04 pp |
|---|---|
| 5Y | −5.55 pp |
| 3Y | −2.06 pp |
| 1Y | −1.15 pp |
| TTM | −0.15 pp |
Revenue by year
| Mar 2017 | ₹431 Cr |
|---|---|
| Mar 2018 | ₹513 Cr |
| Mar 2019 | ₹843 Cr |
| Mar 2020 | ₹1,767 Cr |
| Mar 2021 | ₹1,867 Cr |
| Mar 2022 | ₹2,009 Cr |
| Mar 2023 | ₹2,255 Cr |
| Mar 2024 | ₹2,328 Cr |
| Mar 2025 | ₹2,709 Cr |
| Mar 2026 | ₹3,961 Cr |
Net profit by year
| Mar 2017 | ₹111 Cr |
|---|---|
| Mar 2018 | ₹137 Cr |
| Mar 2019 | ₹171 Cr |
| Mar 2020 | ₹142 Cr |
| Mar 2021 | ₹119 Cr |
| Mar 2022 | ₹309 Cr |
| Mar 2023 | ₹310 Cr |
| Mar 2024 | ₹267 Cr |
| Mar 2025 | ₹347 Cr |
| Mar 2026 | ₹197 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Zydus Wellness Ltd trades at ₹455.85 as of 2026-11-19 with a market cap of ₹14,503 crore. The company shows strong top-line momentum with 74% TTM sales growth and a 26% compounded sales CAGR over 10 years, but profitability has contracted with a -11% TTM profit decline, a PE of 58.9x, and ROE of just 3.38%.
- TTM revenue growth of 74% indicates a sharp acceleration in top-line momentum, suggesting strong demand or successful new product traction
- 10-year compounded sales CAGR of 26% reflects a long track record of consistent revenue expansion in the FMCG space
- 5-year compounded sales CAGR of 16% and 3-year sales CAGR of 21% show sustained mid-to-high-teens revenue growth across multiple time horizons
- Debt-to-equity ratio of 0.55 as of 2026-11-19 is relatively manageable, indicating the balance sheet is not overleveraged
- Stock is trading at ₹455.85 versus a 52-week low of ₹367.55, having recovered roughly 24% from its bottom, suggesting price support at lower levels
- 10-year stock CAGR of 10% shows the company has delivered reasonable long-term capital appreciation for patient holders
- The company is expected to deliver a good upcoming quarter, which could serve as a near-term positive catalyst
- TTM profit has declined 11% and the 3-year compounded profit CAGR is -10%, indicating a persistent and worsening erosion in earnings
- PE ratio of 58.9x as of 2026-11-19 is expensive for a company with shrinking profits, implying the stock prices in significant growth that has not materialized on the bottom line
- ROE stands at just 3.38% as of 2026-11-19, with a 3-year average of about 5% and last year at 4%, well below acceptable thresholds for an FMCG business
- ROCE of 3.43% as of 2026-11-19 suggests poor capital efficiency, meaning the company is generating minimal returns on deployed capital
- Dividend yield of only 0.26% and a payout ratio of just 14.1% of profits over the last 3 years offer negligible income to shareholders
- 5-year compounded profit CAGR of -2% shows the revenue-to-profit conversion has been structurally weak over a half-decade horizon
- Stock trades at ₹455.85, roughly 25% below its 52-week high of ₹611.85, reflecting significant downward pressure from peak levels
- Price-to-book ratio of 2.46x combined with a 3.38% ROE implies the market is paying a premium for assets that generate subpar returns
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Zydus Wellness delivered a strong Q2FY27 with a decisive profitability turnaround — revenue up 73% and EBITDA nearly quadrupling — largely powered by the Comfort Click acquisition. Margins are expanding but remain modest at 7.6%, and the FSSAI label-claim notice bears monitoring as a minor regulatory risk. The stock has gained 12% YTD but sits below its 52-week high of ₹611.85. If integration-driven revenue momentum sustains and margins continue expanding, the trend tilts positive heading into H2FY27.
- Q2 PAT turnaround, EBITDA 4x Nov 3
Zydus Wellness swung to a consolidated net profit of ₹5.1 crore in Q2FY27 from a net loss of ₹52.8 crore YoY. EBITDA surged nearly 4x to ₹85.2 crore with margins expanding 400 bps to 7.6%.
- Revenue surges 73% YoY Nov 3
Consolidated revenue jumped 73.2% YoY to ₹1,126.6 crore from ₹650.5 crore, driven by the Comfort Click acquisition. Standalone net profit rose 53% YoY to ₹116 million.
- Exceptional gain aids profitability Nov 3
Q2FY27 included an exceptional gain of ₹7 crore versus an exceptional loss of ₹16 crore in the base quarter, providing meaningful support to the profitability turnaround.
- Independent director exits after term Nov 17
Kulin S. Lalbhai ceased as Independent Director on November 17, 2026, after completing his second five-year term. This is a routine board succession event.
- FSSAI notice on label claims Oct 23
Zydus Wellness received an FSSAI notice on September 24 regarding product-label claims and responded on October 4, asserting claims are scientifically substantiated.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 440 | 403 | 783 | 841 | 493 | 462 | 913 | 861 | 651 | 965 | 1,485 | 1,437 | 1,127 |
| Expenses | 423 | 391 | 620 | 686 | 473 | 447 | 723 | 705 | 628 | 904 | 1,215 | 1,195 | 1,041 |
| Operating Profit | 16.8 | 12.7 | 162 | 155 | 19.6 | 14.8 | 190 | 156 | 23 | 61 | 270 | 242 | 85.5 |
| OPM % | 3.82% | 3.15% | 20.73% | 18.47% | 3.98% | 3.2% | 20.81% | 18.07% | 3.54% | 6.32% | 18.19% | 16.82% | 7.59% |
| Other Income | 4.1 | 3.4 | 4 | 5 | 4 | 3.8 | 0.8 | 3 | 1.4 | 0.8 | 1.2 | 3.8 | 6.4 |
| Interest | 6.5 | 6.3 | 6.1 | 3.6 | 0.9 | 3.3 | 4.2 | 2.5 | 15.7 | 41.2 | 38.7 | 26.3 | 27.2 |
| Depreciation | 5.8 | 6.1 | 5.7 | 5.1 | 4.9 | 5.2 | 13.2 | 10.8 | 25.1 | 55.5 | 55.3 | 57.1 | 57.1 |
| Exceptional Items | — | — | — | — | 5.9 | — | — | — | −34.2 | −6.6 | — | — | — |
| PBT | 8.6 | 3.7 | 154 | 152 | 23.7 | 10.1 | 173 | 145 | −50.6 | −41.5 | 177 | 162 | 7.6 |
| Tax % | 31.4% | 91.89% | 2.66% | 2.57% | 11.81% | 36.63% | 0.87% | 11.98% | 4.35% | −3.86% | 8.63% | 26.65% | 32.89% |
| Net Profit | 5.9 | 0.3 | 150 | 148 | 20.9 | 6.4 | 172 | 128 | −52.8 | −39.9 | 162 | 119 | 5.1 |
| EPS (₹) | 0.19 | 0.01 | 4.72 | 4.64 | 0.66 | 0.20 | 5.40 | 4.02 | −1.66 | −1.25 | 5.09 | 3.74 | 0.16 |
| YoY Sales growth | 2.52 | −3.17 | 9.76 | 19.78 | 12.05 | 14.56 | 16.68 | 2.37 | 31.97 | 109 | 62.6 | 66.92 | 73.19 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 431 | 397 | 431 | 513 | 843 | 1,767 | 1,867 | 2,009 | 2,255 | 2,328 | 2,709 | 3,961 | 5,013 |
| Expenses | 331 | 305 | 331 | 387 | 658 | 1,446 | 1,522 | 1,664 | 1,918 | 2,020 | 2,329 | 3,451 | 4,355 |
| Operating Profit | 100 | 91 | 99 | 125 | 185 | 321 | 344 | 345 | 337 | 308 | 380 | 510 | 658 |
| OPM % | 23% | 23% | 23% | 24% | 22% | 18% | 18% | 17% | 15% | 13% | 14% | 13% | 13% |
| Other Income | 28 | 32 | 32 | 35 | 28 | 10.71 | 8.94 | 10 | 4.86 | 0 | 13.6 | 6.4 | 6 |
| Interest | 0 | 0 | 1 | 2 | 30 | 140 | 84 | 26 | 16 | 24 | 12 | 98 | 133 |
| Depreciation | 8 | 7 | 7 | 9 | 13 | 26 | 25 | 24 | 25 | 24 | 28 | 147 | 225 |
| Exceptional Items | — | — | — | — | — | −44.2 | −132 | — | −10.05 | — | 5.9 | −40.8 | — |
| PBT | 120 | 117 | 124 | 150 | 171 | 121 | 112 | 306 | 291 | 260 | 359 | 230 | 306 |
| Tax % | 7% | 10% | 10% | 9% | 0% | −17% | −6% | −1% | −7% | −3% | 3% | 14% | — |
| Net Profit | 111 | 105 | 111 | 137 | 171 | 142 | 119 | 309 | 310 | 267 | 347 | 197 | 246 |
| EPS (₹) | 5.58 | 5.28 | 5.58 | 6.85 | 5.87 | 4.92 | 3.73 | 9.71 | 9.75 | 8.39 | 10.90 | 6.20 | 7.74 |
| Div. Payout % | 22% | 25% | 23% | 23% | 17% | 20% | 27% | 10% | 10% | 12% | 11% | 19% | — |
| Sales growth | 7 | −8 | 9 | 19 | 64 | 110 | 6 | 8 | 12 | 3 | 16 | 46 | 74 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 39 | 39 | 39 | 58 | 58 | 64 | 64 | 64 | 64 | 64 | 64 | 64 |
| Reserves | 367 | 439 | 518 | 652 | 3,329 | 3,403 | 4,504 | 4,780 | 5,059 | 5,294 | 5,608 | 5,762 | 5,844 |
| Borrowings | 0 | 0 | 25 | 25 | 1,569 | 1,519 | 550 | 387 | 297 | 329 | 188 | 3,203 | 3,167 |
| Other Liabilities | 102 | 89 | 100 | 112 | 503 | 610 | 548 | 461 | 413 | 462 | 582 | 1,161 | 1,277 |
| Total Liabilities | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 10,190 | 10,352 |
| Fixed Assets | 84 | 82 | 103 | 104 | 4,567 | 4,674 | 4,667 | 4,710 | 4,732 | 4,708 | 5,125 | 8,596 | 8,602 |
| CWIP | 0 | 0 | 0 | 0 | 10 | 4 | 4 | 12 | 13 | 10 | 15 | 23 | 18 |
| Investments | 0 | 94 | 30 | 148 | 46 | 110 | 0 | 27 | 70 | 78 | 36 | 5 | 223 |
| Other Assets | 423 | 391 | 550 | 577 | 835 | 802 | 995 | 943 | 1,018 | 1,354 | 1,266 | 1,566 | 1,509 |
| Total Assets | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 10,190 | 10,352 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 69 | 90 | 77 | 69 | 149 | 259 | 287 | 237 | 92 | 246 | 380 | 226 |
| Investing | 29 | −28 | −72 | −59 | −4,092 | −17 | −10 | −59 | −85 | −178 | −207 | −2,881 |
| Financing | −27 | −58 | −6 | −2 | 4,052 | −260 | −216 | −234 | −138 | −26 | −186 | 2,698 |
| Net Cash Flow | 71 | 4 | −1 | 8 | 109 | −18 | 60 | −56 | −132 | 43 | −13 | 44 |
| Free Cash Flow | 72 | 86 | 46 | 61 | 132 | 235 | 269 | 162 | 47 | 220 | 315 | 126 |
| CFO/EBITDA | 80 | 114 | 86 | 64 | 115 | 81 | 83 | 70 | 28 | 81 | 99 | 50 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1 | 3 | 3 | 6 | 42 | 24 | 18 | 26 | 34 | 44 | 49 | 35 |
| Inventory Days | 76 | 73 | 127 | 113 | 393 | 168 | 158 | 135 | 146 | 150 | 148 | 178 |
| Days Payable | 146 | 191 | 264 | 254 | 662 | 289 | 189 | 136 | 100 | 116 | 122 | 107 |
| Cash Conversion Cycle | −69 | −116 | −134 | −135 | −227 | −97 | −13 | 25 | 80 | 78 | 75 | 106 |
| Working Capital Days | −37 | −38 | −57 | −26 | −26 | −7 | −35 | −27 | 17 | 20 | 34 | 48 |
| ROCE % | 32% | 26% | 23% | 22% | 7% | 6% | 6% | 6% | 6% | 5% | 6% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Zydus Wellness insights
77 extracted metrics across FY09–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Mar 2026PPT
- Concall · Mar 2026PPT
- 19 Nov 2020
- 29 Oct 2020
- 8 Oct 2020
- 10 Aug 2020
- 2 Jan 2020
- General announcements 20 Nov 2026
- General announcements 3 Nov 2026
Frequently Asked Questions about Zydus Wellness
What does Zydus Wellness Ltd do?
Where is Zydus Wellness Ltd (ZYDUSWELL) listed?
Which sector does Zydus Wellness Ltd belong to?
What is the market capitalisation of Zydus Wellness Ltd?
What is the PE ratio of Zydus Wellness Ltd?
What is the 52-week high and low of Zydus Wellness Ltd?
Does Zydus Wellness Ltd pay dividends?
What is the Return on Equity (ROE) of Zydus Wellness Ltd?
Company Information
Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSWELL.md for Zydus Wellness Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.